Medication and Technologies

Thursday, May 2, 2019: 1:30 PM-2:25 PM
Room: 518 (Palais des congres de Montreal)
1:30 PM
Effects of Balovaptan on Health-Related Quality of Life of Adult Males with Autism Spectrum Disorder: Results from a Phase 2 Randomized Double-Blind Placebo-Controlled Study (VANILLA)
T. Willgoss L. Squassante F. Bolognani J. W. Smith L. Murtagh P. Fontoura O. Khwaja D. Umbricht K. Sanders M. del Valle Rubido
1:42 PM
Cannabidiol (CBD) Alters Low Frequency Activity and Functional Connectivity in the Brain in Autism Spectrum Disorder (ASD).
C. M. Pretzsch J. Freyberg B. Voinescu M. A. Mendez R. H. Wichers L. Ajram G. Ivin M. Heasman S. C. Williams D. G. Murphy E. Daly G. M. McAlonan
1:54 PM
A Placebo-Controlled Trial of Cannabinoids in Children with ASD
A. Aran M. Harel L. Polyansky A. Schnapp N. Barnoy N. Wattad D. Shmueli Y. Pollak H. Cassuto
2:06 PM
Feasibility and Safety of Immersive Virtual Reality As a Tool to Improve Police Safety in Adolescents and Adults with Autism Spectrum Disorder
A. Zitter R. Solorzano S. Turnacioglu J. S. Miller V. Ravindran J. Parish-Morris J. McCleery